Bristol-Myers Squibb: Infections trials

The registry lists 22 Infections studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 2Phase 2 6Phase 3 2Phase 4 2No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTerminatedNCT01866930Phase 3Results posted
• Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)CompletedNCT01017575Phase 2Results posted
• Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese PatientsCompletedNCT01016912Phase 2Results posted
• Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) InfectionCompletedNCT00371150Phase 4Results posted
• Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B InfectionCompletedNCT00096785Phase 3Results posted
• Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCompletedNCT01708889Phase 1
• Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naiveTerminatedNCT01489046Phase 2
• An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) SubjectCompletedNCT01051414Phase 2
• Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionStatus unknownNCT01001754Phase 2
• Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT00565539Phase 1
• Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)CompletedNCT00382460Phase 4
• An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV InfectionNo longer availableNCT00162227
• An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: CanadaNo longer availableNCT00162188
• Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature InfantsCompletedNCT00113191Not applicable
• The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsTerminatedNCT00002418Phase 2
• A Study of Lobucavir in Patients With AIDSCompletedNCT00002352Not applicable
• A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.CompletedNCT00002349Not applicable
• A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV DrugsCompletedNCT00002308Not applicable
• A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected PatientsCompletedNCT00002307Not applicable
• A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related SyndromesCompletedNCT00002293Not applicable
• A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV InfectionCompletedNCT00002177Not applicable
• A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV InfectionCompletedNCT00002176Not applicable